Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients Initiation of Phase 1a/2b STK11 mutated NSCLC trial planned for 2H22 BerGenBio to host conference call and webcast today at 10:00 AM CEST/4:00 AM EDT BERGEN, Norway, Aug. 23, 2022 /PRNewswire/ -- BerGenBio ASA (OSE:...